The PE Ratio as of July 2024 (TTM) for Arrowhead Pharmaceuticals, Inc. (ARWR) is -6.66

According to Arrowhead Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -6.66. This represents a change of -8.04% compared to the average of -7.24 of the last 4 quarters.

Arrowhead Pharmaceuticals, Inc. (ARWR) Historical PE Ratio (quarterly & annually)

How has ARWR PE Ratio performed in the past?

The mean historical PE Ratio of Arrowhead Pharmaceuticals, Inc. over the last ten years is -15.17. The current -6.66 PE Ratio has changed 4.29% with respect to the historical average. Over the past ten years (40 quarters), ARWR's PE Ratio was at its highest in in the September 2019 quarter at 57.39. The PE Ratio was at its lowest in in the December 2019 quarter at -575.83.

Arrowhead Pharmaceuticals, Inc. (ARWR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Arrowhead Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Arrowhead Pharmaceuticals, Inc. (ARWR) Average PE Ratio

How has ARWR PE Ratio performed in the past?

The current PE Ratio of Arrowhead Pharmaceuticals, Inc. (ARWR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Arrowhead Pharmaceuticals, Inc. (ARWR) PE Ratio vs. Peers

How is ARWR’s PE Ratio compared to its peers?

Arrowhead Pharmaceuticals, Inc.’s PE Ratio is greater than Wave Life Sciences Ltd. (-13.69), less than CytomX Therapeutics, Inc. (7.44), less than Assembly Biosciences, Inc. (-1.60), less than Neoleukin Therapeutics, Inc. (-0.98), less than BioMarin Pharmaceutical Inc. (77.76), less than Incyte Corporation (20.66), greater than Ionis Pharmaceuticals, Inc. (-19.50), greater than Apellis Pharmaceuticals, Inc. (-11.71), less than ProQR Therapeutics N.V. (-5.28), less than Annexon, Inc. (-6.34), less than Day One Biopharmaceuticals, Inc. (-6.65), greater than Terns Pharmaceuticals, Inc. (-7.36), less than Mirati Therapeutics, Inc. (-5.32), less than Amylyx Pharmaceuticals, Inc. (-1.88), greater than IVERIC bio, Inc. (-33.43), greater than Blueprint Medicines Corporation (-23.96), greater than Karuna Therapeutics, Inc. (-29.52),

Build a custom stock screener for Arrowhead Pharmaceuticals, Inc. (ARWR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arrowhead Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Arrowhead Pharmaceuticals, Inc. (ARWR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Arrowhead Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.